BST2 and Miyoshi myopathy: Humanized monoclonal antibody (McAb) against CD317 showed significant tumor growth inhibition and prolonged survival in human MM xenograft models and MM patients, and the antitumor effect of CD317 McAb were largely mediated by natural killer (NK) cell and monocyte- and macrophage-mediated antibody-dependent cellular cytotoxicity (ADCC) [17].